##plugins.themes.academic_pro.article.main##
Abstract
Chronic obstructive pulmonary disease (COPD) is a pressing problem in the modern world. Every year, COPD increasingly leads to temporary disability and death. This is why it is so important to predict the progression of COPD in time. Progression of the disease can lead to severe shortness of breath, frequent exacerbations of COPD, respiratory failure and death. This literature review examines radiological and functional markers, clinical manifestations, sputum and blood markers, and the lung microbiome. All of this may be useful for predicting the risk of COPD progression.
Keywords
COPD
disease progression
markers
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Fattakhova Yuliya Edgarovna, & Matrzayeva Shoira Gulimboyevna. (2024). Markers Of Progression of Chronic Obstructive Pulmonary Disease. Texas Journal of Medical Science, 32, 70–77. https://doi.org/10.62480/tjms.2024.vol32.pp70-77
References
- ведущих причин смерти в мире. URL: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
- Анаев Э. Х. Биологические маркеры при хронической обструктивной болезни легких //Практическая пульмонология. – 2018. – №. 1. – C. 26-32.
- Бремя хронических обструктивных болезней легких. URL: https://www.who.int/respiratory/copd/burden/ru/
- Виткина Т. И., Сидлецкая К. А., Денисенко Ю. К. Изменение экспрессии рецептора к IL-6 на поверхности иммунокомпетентных клеток при прогрессировании хронической обструктивной болезни легких //Медицинская иммунология. – 2017. – Т. 19. – №. 2. – C. 191-196.
- Калинина Е. П., Лобанова Е. Г. Диагностический критерий прогрессирования хронической обструктивной болезни легких //Сибирский научный медицинский журнал. – 2010. – Т. 30. – №. 1. – C.5-7.
- Кубышева Н. И. и др. Значение растворимых молекул клеточной адгезии, метаболитов оксида азота, эндотелина-1 и их ассоциаций как маркеров прогрессирования воспаления при ХОБЛ //Современные технологии в медицине. – 2017. – Т. 9. – №. 2. – C.105-115.
- Любавина Н. А. и др. Сывороточное содержание растворимых антигенов адгезии как маркер прогрессирования хронической обструктивной болезни легких //Современные технологии в медицине. – 2011. – №. 1. – C.67-71.
- Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких (2014). URL: http://www.pulmonology.ru/ publications/guide.php.
- Хроническая обструктивная болезнь легких (ХОБЛ). URL: https://www.who.int/ru/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
- Agusti A., Sin D. D. Biomarkers in COPD //Clinics in chest medicine. – 2014. – Т. 35. – №. 1. – С. 131-141.
- Apweiler R. et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics //Clinical chemistry and laboratory medicine. – 2009. – Т. 47. – №. 6. – С. 724-744.
- Argyriou Е., Atmatzidou V., Bellou А. Economic and social burden of chronic obstructive pulmonary disease // Ann Transl Med. -2016. -T.4– №. 22. - C.1021
- Barnes P. J., Ito K., Adcock I. M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase //The Lancet. – 2004. – Т. 363. – №. 9410. – С. 731-733.
- Beeh K. M. et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD //Chest. – 2003. – Т. 123. – №. 3. – С. 778-783.
- Casaburi R. et al. The COPD biomarker qualification consortium (CBQC) //COPD: Journal of Chronic Obstructive Pulmonary Disease. – 2013. – Т. 10. – №. 3. – С. 367-377.
- Celli B. R. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease //New England Journal of Medicine. – 2004. – Т. 350. – №. 10. – С. 1005-1012.
- Coxson H. O. et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study //The lancet Respiratory medicine. – 2013. – Т. 1. – №. 2. – С. 129-136.
- Dahl M. et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease //American journal of respiratory and critical care medicine. – 2007. – Т. 175. – №. 3. – С. 250-255.
- Dahl M. et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease //American journal of respiratory and critical care medicine. – 2001. – Т. 164. – №. 6. – С. 1008-1011.
- Dijkstra A. E. et al. Low-dose CT measurements of airway dimensions and emphysema associated with airflow limitation in heavy smokers: a cross sectional study //Respiratory research. – 2013. – Т. 14. – №. 1. – С. 1-9.
- Faner R. et al. Lessons from ECLIPSE: a review of COPD biomarkers //Thorax. – 2014. – Т. 69. – №. 7. – С. 666-672.
- Galbán C. J. et al. Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression //Nature medicine. – 2012. – Т. 18. – №. 11. – С. 1711-1715.
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Medical Communications Resources, Inc., 2014. Accessed 12 July 2014. Available online: www.goldcopd.com
- GOLD (Global Initiative for Chronic Obstructive Lung Disease) [Internet]. Global strategy for the diagnosis, management, and prevention of COPD. 2017 [cited 2018 May 29]. Available from: http: // goldcopd.org/ download/326/
- Han M. L. K. et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes //Radiology. – 2011. – Т. 261. – №. 1. – С. 274-282.
- Haruna A. et al. CT scan findings of emphysema predict mortality in COPD //Chest. – 2010. – Т. 138. – №. 3. – С. 635-640.
- Hoesein F. A. A. M. et al. CT-quantified emphysema in male heavy smokers: association with lung function decline //Thorax. – 2011. – Т. 66. – №. 9. – С. 782-787.
- Hurst J. R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease //American journal of respiratory and critical care medicine. – 2006. – Т. 174. – №. 8. – С. 867-874.
- Johannessen A. et al. Mortality by level of emphysema and airway wall thickness //American journal of respiratory and critical care medicine. – 2013. – Т. 187. – №. 6. – С. 602-608.
- Keatings V. et al. Analysis of fluidphase mediators //European Respiratory Journal. – 2002. – Т. 20. – №. 37 suppl. – С. 24s-39s.
- Koutsokera A. et al. Pulmonary biomarkers in COPD exacerbations: a systematic review //Respiratory research. – 2013. – Т. 14. – №. 1. – С. 1-12.
- Litmanovich D. E. et al. Multidetector computed tomographic imaging in chronic obstructive pulmonary disease: emphysema and airways assessment //Radiologic Clinics. – 2014. – Т. 52. – №. 1. – С. 137-154.
- Man S. F. P. et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease //Thorax. – 2006. – Т. 61. – №. 10. – С. 849-853.
- Paone G. et al. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients //Disease markers. – 2011. – Т. 31. – №. 2. – С. 91-100.
- Pavlov P., Ivanov Y., Glogovska P., et al. New epidemiology data on COPD in the Pleven region // Thoracic Med. -2012. -T. 2 – №. IV. -C. 44–50.
- Pontén F. et al. A global view of protein expression in human cells, tissues, and organs //Molecular systems biology. – 2009. – Т. 5. – №. 1. – С. 337.
- Rangelov K., Sethi S. Role of infections //Clinics in chest medicine. – 2014. – Т. 35. – №. 1. – С. 87-100.
- Samy N. et al. Clinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease //NY Sci. J. – 2010. – Т. 6. – С. 25-32.
- Shaaban R. et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study //Respiratory medicine. – 2006. – Т. 100. – №. 12. – С. 2112-2120.
- Sin D. D. et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease //Thorax. – 2005. – Т. 60. – №. 12. – С. 992-997.
- Sin D. D. et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease //American journal of respiratory and critical care medicine. – 2008. – Т. 177. – №. 11. – С. 1207-1214.
- Smith B. M. et al. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study //The American journal of medicine. – 2014. – Т. 127. – №. 1. – С. 94. e7-94. e23.
- Stockley R. A. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? //International journal of chronic obstructive pulmonary disease. – 2014. – Т. 9. – С. 163.
- Tachkov K, Kamusheva M, Pencheva V, et al. Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD) // Biotechnol Biotechnol Equip. -2017. -T.31. – №. 4. -C. 855–861.
- Tsoumakidou M., Tzanakis N., Siafakas N. M. Induced sputum in the investigation of airway inflammation of COPD //Respiratory medicine. – 2003. – Т. 97. – №. 8. – С. 863-871.
- Tufvesson E., Ekberg M., Bjermer L. Inflammatory biomarkers in sputum predict COPD exacerbations //Lung. – 2013. – Т. 191. – №. 4. – С. 413-416.
- Valvi D. et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts //International journal of chronic obstructive pulmonary disease. – 2012. – Т. 7. – С. 173.
- Vestbo J. et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE) //European Respiratory Journal. – 2008. – Т. 31. – №. 4. – С. 869-873.
- Vestbo J. et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE?. A clinical perspective from the study team //American journal of respiratory and critical care medicine. – 2014. – Т. 189. – №. 9. – С. 1022-1030.
- Wheaton A. G. et al. Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013 //MMWR. Morbidity and mortality weekly report. – 2015. – Т. 64. – №. 11. – С. 289.
- Wheaton A. G. et al. Pulmonary function, chronic respiratory symptoms, and health-related quality of life among adults in the United States–National Health and Nutrition Examination Survey 2007–2010 //BMC public health. – 2013. – Т. 13. – №. 1. – С. 1-9.
- Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy //Clinical Pharmacology & Therapeutics. – 2010. – Т. 88. – №. 6. – С. 765-773.
- Zemans R. L. et al. Multiple biomarkers predict disease severity, progression and mortality in COPD //Respiratory research. – 2017. – Т. 18. – №. 1. – С. 1-10.
- Zulueta J. J. et al. Emphysema scores predict death from COPD and lung cancer //Chest. – 2012. – Т. 141. – №. 5. – С. 1216-1223.